Skip to main content
TipRanks
Go Ultimate75% OFF

TG Therapeutics (TGTX) AI Stock Analysis

2,177 Followers
TGTX

TG Therapeutics

(NASDAQ:TGTX)

Select Model
Rating:72Outperform
Price Target:$66.00â–²(5.25% Upside)
Action:reiterated
Date:11/10/26

The score is driven primarily by improving fundamentals (rapid revenue growth and sustained profitability) and a strongly positive earnings update with raised guidance. Technicals also support the view with an established uptrend. The main constraint is valuation risk from a very high P/E and the remaining need to prove consistent cash conversion and stable profitability over time.

Positive Factors
BRIUMVI revenue growth and adoptionSustained sequential growth and expanding new-patient starts indicate that BRIUMVI is building durable commercial traction rather than relying on a single launch period. Continued adoption, persistence, and prescriber expansion can support revenue compounding over the next several quarters.
Negative Factors
Gross-to-net pressureIncreasing rebates, government discounts, and payer concessions can reduce the net revenue captured from each BRIUMVI treatment even when demand grows. Persistent gross-to-net pressure could limit margin expansion and require greater commercial spending to preserve access and market share.

TG Therapeutics (TGTX) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%TGTX+96.28%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$9.48B
Dividend Yield
―
Average Volume (3M)
1.92M
Price to Earnings (P/E)
84.4
Beta (1Y)
0.34
Revenue Growth
68.78%
EPS Growth
-75.71%
Country
US
Employees
399
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

TG Therapeutics Business Overview & Revenue Model

Company Description

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solution...

How the Company Makes Money

TG Therapeutics makes money primarily through net product revenue from sales of BRIUMVI in the United States. Revenue is generated when the company sells product to specialty distributors and other customers (e.g., specialty pharmacies), and recogniz...

TG Therapeutics Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:4.82%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly positive, with record commercial performance, raised 2026 revenue guidance, sustained BRIUMVI clinical results, improving profitability, share repurchases, and multiple expansion opportunities across simplified IV dosing, subcutaneous administration, azer-cel, and additional indications. The company noted ongoing gross-to-net pressure, early-stage data and regulatory dependencies, but characterized the 340B exposure as limited and continued to describe its commercial and financial outlook as strong.

Positive Updates

Revenue Guidance Raised to Approximately $1 Billion
Third-quarter global revenue was approximately $260 million, including $233 million in U.S. BRIUMVI net revenue. With solid third-quarter performance and trends pointing to a strong fourth quarter, the company raised full-year 2026 global revenue guidance to approximately $1 billion.

Negative Updates

Ongoing Gross-to-Net Pressure
Management acknowledged that gross-to-net will face pressure over time from contracting, payer mix, government discounts, and other factors. The company uses price increases to help offset these discounts and keep net price as stable as possible.

Company Guidance

TG Therapeutics raised its full year global revenue guidance to $1 billion for 2026, including full-year U.S. BRIUMVI net product revenue guidance from $890 million to $905 million to a new range of $915 million to $920 million, reflecting more than $260 million for the fourth quarter; it also expects approximately $1 billion in total global revenue, including projected payments from its ex-U.S. partner. Full-year R&D and SG&A expenses, excluding stock-based comp, are expected to be in line with prior guidance of $450 million-$500 million. The company is targeting a potential approval of the consolidated IV initiation dose around mid-2027, with the impact expected to emerge in the latter part of the second half of 2027 and into 2028, while Phase III results for subcu BRIUMVI are expected around year-end or early 2027 and a potential commercial launch is targeted for 2028. The company has not given guidance for 2027 and expects minimal impact from 340B policy changes, with 340B representing maybe about 5% of its business.

TG Therapeutics Financial Statement Overview

Summary

Strong revenue scale-up and improved profitability (TTM revenue ~$897.8M, ~11.3% EBIT margin, ~82.7% gross margin) support a solid score. Offsetting this are profitability volatility (notably an unusually high 2025 net margin versus other periods) and historically inconsistent cash generation, with cash conversion still modest in the TTM period.

Income Statement

78Positive

Balance Sheet

70Positive

Cash Flow

62Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue897.76M616.29M329.00M233.66M2.79M6.69M
Gross Profit742.84M515.57M290.52M219.53M2.52M5.90M
EBITDA191.33M134.36M49.90M26.10M-213.11M-341.97M
Net Income106.06M447.18M23.38M12.67M-223.81M-348.10M
Balance Sheet
Total Assets1.59B1.06B577.69M329.59M193.57M379.63M
Cash, Cash Equivalents and Short-Term Investments504.67M141.97M311.00M217.51M161.68M314.76M
Total Debt754.37M260.73M253.72M110.80M83.06M79.05M
Total Liabilities1.02B415.23M355.33M169.09M134.99M142.48M
Stockholders Equity572.13M648.02M222.36M160.50M58.59M237.15M
Cash Flow
Free Cash Flow85.56M-24.99M-40.56M-31.41M-176.18M-296.04M
Operating Cash Flow86.26M-24.77M-40.52M-31.41M-176.17M-295.63M
Investing Cash Flow-23.14M13.80M-1.04M-50.65M-20.01M-332.00K
Financing Cash Flow292.23M-89.73M128.53M72.70M-391.00K41.42M

TG Therapeutics Technical Analysis

Technical Analysis SentimentPositive
Last Price62.71

Price Trends

50DMA56.97Positive
100DMA55.28Positive
200DMA45.71Positive

Market Momentum

MACD2.29Negative
RSI59.16Neutral
STOCH64.97Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Positive. The current price of 62.71 is above the 20-day moving average (MA) of 59.82, above the 50-day MA of 56.97, and above the 200-day MA of 45.71, indicating a bullish trend. The MACD of 2.29 indicates Negative momentum. The RSI at 59.16 is Neutral, neither overbought nor oversold. The STOCH value of 64.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TGTX.

TG Therapeutics Risk Analysis

TG Therapeutics disclosed 74 risk factors in its most recent earnings report. TG Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We have a history of losses and our ability to maintain profitability in the future remains uncertain. We expect to incur significant expenses for the foreseeable future as we commercialize BRIUMVI and advance our product candidates through clinical trials, seek regulatory approvals and pursue commercialization.Q3, 2026
2.We may seek additional capital to support our business, strategic initiatives or other corporate purposes, and if adequate financing is not available when needed, our business and growth prospects could be adversely affected.Q3, 2026
3.We may be unable to successfully develop, obtain regulatory approval for, or commercialize a subcutaneous formulation of our approved intravenous product, which could limit our ability to expand our market opportunity and patient reach.Q4, 2025

TG Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TGTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ARQTARQT79Outperform$3.46B116.1114.18%―60.00%―
PTGXPTGX72Outperform$8.14B24.0942.83%―163.69%574.89%
TGTXTGTX72Outperform$9.48B84.4517.62%―68.78%-75.71%
KYMRKYMR60Neutral$10.37B-33.58-22.39%―133.77%-0.64%
IMVTIMVT53Neutral$6.87B-12.91-63.01%――9.82%
LEGNLEGN52Neutral$3.12B-1612.68-0.02%―49.73%98.75%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%TGTXPTGXIMVTARQTLEGNKYMRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TGTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TGTXTG Therapeutics62.7132.26105.94%
PTGXProtagonist Therapeutics Inc124.6740.4748.06%
IMVTImmunovant, Inc.33.2110.4245.72%
ARQTArcutis Biotherapeutics Inc27.330.000.00%
LEGNLegend Biotech Corporation16.11-11.42-41.48%
KYMRKymera Therapeutics, Inc.121.5256.8988.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026